In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Just one year after its launch, Juno Therapeutics Inc. (chimeric antigen receptor T-cell (CART) technology for cancer drug development) netted $283mm through its initial public offering of 12.7mm shares (including the overallotment) at $24. The IPO (one of the largest for a US biopharma company in 2014) was greatly upsized: after filing in November, Juno set an initial range earlier this month of 9.25mm shares at $15-18, and a few days before pricing increased the potential per-share price to $21-23.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?